Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis

BACKGROUND: Untreated hemophilia A patients may experience recurrent bleeding events leading to debilitating joint damages. While RCT and pharmacokinetic data support the value of Kovaltry [an unmodified full-length recombinant factor VIII (FVIII) product], real world evidence in children is lacking...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Orphanet J Rare Dis
Autori principali: O’Hara, Jamie, Hirst, Ceri, Cabre Marquez, Jose Francisco, Burke, Tom
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Letter to the Editor
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809751/
https://ncbi.nlm.nih.gov/pubmed/33451335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-021-01676-w
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi